Inhaltsbereich
| 218 Einträge | « ‹ 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 › » |
Seite 8 / 11
 Druckansicht
|
| Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT. |
| Steger GG, Egle D, Bartsch R, Pfeiler G, Petru E, Greil R, Helfgott R, Marth C, Öhler L, Hubalek M, Lang A, Tinchon C, Haslbauer F, Redl A, Hock K, Hennebelle M, Mraz B, Gnant M |
| Breast (Edinburgh, Scotland). 2020 Jan 31. pii: S0960-9776(20)30036-9. doi: 10.1016/j.breast.2020.01.035 |
| PMID: 32062536 |
| Hypothyroidism is associated with improved survival prognosis in patients with newly diagnosed brain metastases. |
| Wippel C, Starzer AM, Berghoff ASS, Bergen E, Wolf P, Widhalm G, Frischer JM, Gatterbauer B, Marosi C, Dieckmann K, Bartsch R, Preusser M |
| Annals of oncology : official journal of the European Society for Medical Oncology. pii: S0923-7534(19)48795-4. doi: 10.1093/annonc/mdy273.366 |
| PMID: 32136167 |
| Androgen receptor expression in breast cancer brain metastases. |
| Bergen ES, Berghoff ASS, Rajky U, Rudas M, Bago-Horvath Z, Exner R, Dieckmann K, Widhalm G, Gnant MI, Zielinski CC, Steger GG, Preusser M, Bartsch R |
| Annals of oncology : official journal of the European Society for Medical Oncology. pii: S0923-7534(19)48796-6. doi: 10.1093/annonc/mdy273.367 |
| PMID: 32136166 |
| Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34). |
| Singer CF, Pfeiler G, Hubalek M, Bartsch R, Stöger H, Pichler A, Petru E, Bjelic-Radisic V, Greil R, Rudas M, Maria Tea MK, Wette V, Petzer AL, Sevelda P, Egle D, Dubsky PC, Filipits M, Fitzal F, Exner R, Jakesz R, Balic M, Tinchon C, Bago-Horvath Z, Frantal S, Gnant M |
| European journal of cancer (Oxford, England : 1990). 2020 Apr 20. pii: S0959-8049(20)30159-3. doi: 10.1016/j.ejca.2020.03.018 |
| PMID: 32325419 |
| Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry. |
| Bartsch R, Frings S, Marty M, Awada A, Berghoff AS, Conte P, Dickin S, Enzmann H, Gnant M, Hasmann M, Hendriks HR, Llombart A, Massacesi C, von Minckwitz G, Penault-Llorca F, Scaltriti M, Yarden Y, Zwierzina H, Zielinski CC |
| Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Dec 18. pii: S0923-7534(19)36495-6. doi: 10.1093/annonc/mdt531 |
| PMID: 24351401 |
| Circumnavigating the challenges of COVID-19 in oncology. |
| Fuereder T, Gunsilius E, Bartsch R, Hilbe W |
| Memo. 2020 May 7. doi: 10.1007/s12254-020-00611-2. pii: 611. pmc: PMC7203542 |
| PMID: 32382356 |
| Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer. |
| Berghoff AS, Wippel C, Starzer AM, Ballarini N, Wolpert F, Bergen E, Wolf P, Steindl A, Widhalm G, Gatterbauer B, Marosi C, Dieckmann K, Bartsch R, Scherer T, Koenig F, Krebs M, Weller M, Preusser M |
| European journal of cancer (Oxford, England : 1990). 2020 Jun 27. pii: S0959-8049(20)30277-X. doi: 10.1016/j.ejca.2020.05.011 |
| PMID: 32603949 |
| Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression. |
| Zagouri F, Zoumpourlis P, Le Rhun E, Bartsch R, Zografos E, Apostolidou K, Dimopoulos MA, Preusser M |
| Cancer treatment reviews. 2020 Jun 3. pii: S0305-7372(20)30084-0. doi: 10.1016/j.ctrv.2020.102046 |
| PMID: 32599393 |
| Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer. |
| Bartsch R |
| Expert opinion on investigational drugs. 2020 Jul 23. doi: 10.1080/13543784.2020.1792443 |
| PMID: 32701032 |
| ASCO 2020. |
| Bartsch R, Dieras V, Cortes J, Müller V, Ruhstaller T |
| Breast care (Basel, Switzerland). 2020 Jul 16. doi: 10.1159/000510051. pii: brc-0015-0433. pmc: PMC7490662 |
| PMID: 32982656 |
| Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field. |
| Marhold M, Topakian T, Agis H, Bartsch R, Berghoff AS, Brodowicz T, Fuereder T, Ilhan-Mutlu A, Kiesewetter B, Krainer M, Locker GJ, Marosi C, Prager G, Schmidinger M, Thallinger C, Zöchbauer-Müller S, Raderer M, Preusser M, Lamm W |
| ESMO open. pii: esmoopen-2020-000880. doi: 10.1136/esmoopen-2020-000880 |
| PMID: 33051192 |
| Targeted Therapy Recommendations for Therapy Refractory Solid Tumors-Data from the Real-World Precision Medicine Platform MONDTI. |
| Taghizadeh H, Unseld M, Spalt M, Mader RM, Müllauer L, Fuereder T, Raderer M, Sibilia M, Hoda MA, Aust S, Polterauer S, Lamm W, Bartsch R, Preusser M, A KW, Prager GW |
| Journal of personalized medicine. 2020 Oct 23. pii: jpm10040188. doi: 10.3390/jpm10040188 |
| PMID: 33114048 |
| Expectations and perception of cancer treatment goals in previously untreated patients. The EXPECT trial. |
| Minichsdorfer C, Zeller O, Kirschbaum M, Berghoff AS, Bartsch R |
| Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2020 Nov 7. doi: 10.1007/s00520-020-05826-x. pii: 10.1007/s00520-020-05826-x |
| PMID: 33159221 |
| Results from the FeDeriCa trial: are we reducing the burden of breast cancer treatment? |
| Bartsch R, Minichsdorfer C, Kolberg-Liedtke C |
| The Lancet. Oncology. 2020 Dec 17. pii: S1470-2045(20)30636-7. doi: 10.1016/S1470-2045(20)30636-7 |
| PMID: 33357419 |
| ASCO 2020: highlights in breast cancer. |
| Bartsch R |
| Memo. 2021 Jan 24. doi: 10.1007/s12254-021-00674-9. pii: 674. pmc: PMC7829038 |
| PMID: 33520003 |
| Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. |
| Onesti CE, Tagliamento M, Curigliano G, Harbeck N, Bartsch R, Wildiers H, Tjan-Heijnen V, Martin M, Rottey S, Generali D, Campone M, Cristofanilli M, Pusztai L, Peeters M, Berchem G, Cortes J, Ruhstaller T, Ciruelos E, Rugo HS, Jerusalem G |
| JCO global oncology. doi: 10.1200/GO.20.00589 |
| PMID: 33529077 |
| PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial. |
| Fitzal F, Filipits M, Fesl C, Rudas M, Greil R, Balic M, Moinfar F, Herz W, Dubsky P, Bartsch R, Ferree S, Schaper C, Gnant M |
| The British journal of surgery. 2021 Feb 20. pii: 6145316. doi: 10.1093/bjs/znaa089 |
| PMID: 33608712 |
| Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer. |
| Jackisch C, Barcenas CH, Bartsch R, Palma JD, Glück S, Harbeck N, Macedo G, O'Shaughnessy J, Pistilli B, Ruiz-Borrego M, Rugo HS |
| Clinical breast cancer. 2021 Feb 6. pii: S1526-8209(21)00043-4. doi: 10.1016/j.clbc.2021.02.001 |
| PMID: 33678567 |
| Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34. |
| Bartsch R, Singer CF, Pfeiler G, Hubalek M, Stoeger H, Pichler A, Petru E, Bjelic-Radisic V, Greil R, Rudas M, Muy-Kheng TM, Wette V, Petzer AL, Sevelda P, Egle D, Dubsky PC, Filipits M, Fitzal F, Exner R, Jakesz R, Balic M, Tinchon C, Bago-Horvath Z, Frantal S, Gnant M |
| British journal of cancer. 2021 Mar 24. doi: 10.1038/s41416-021-01284-2. pii: 10.1038/s41416-021-01284-2 |
| PMID: 33762716 |
| ESMO 2020: highlights in breast cancer. |
| Bartsch R |
| Memo. 2021 Apr 30. doi: 10.1007/s12254-021-00713-5. pii: 713. pmc: PMC8090520 |
| PMID: 33968263 |
| 218 Einträge | « ‹ 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 › » |
Seite 8 / 11
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
